|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
53,520,000 |
Market
Cap: |
36.18(M) |
Last
Volume: |
446,593 |
Avg
Vol: |
445,379 |
52
Week Range: |
$0.676 - $0.676 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
386,399 |
680,912 |
680,912 |
680,912 |
Total Buy Value |
$353,333 |
$620,149 |
$620,149 |
$620,149 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
28 |
40 |
40 |
40 |
Total Shares Sold |
0 |
0 |
30,110 |
30,110 |
Total Sell Value |
$0 |
$0 |
$26,460 |
$26,460 |
Total People Sold |
0 |
0 |
2 |
2 |
Total Sell Transactions |
0 |
0 |
5 |
5 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Smith Lawrence Russell |
VP, Vaccine Research |
|
2015-10-12 |
4 |
AS |
$0.43 |
$415 |
D/D |
(974) |
242,055 |
|
- |
|
Samant Vijay B |
President & CEO |
|
2015-10-12 |
4 |
AS |
$0.41 |
$1,962 |
D/D |
(4,738) |
1,141,563 |
|
- |
|
Ramos Anthony Alan |
VP, Chief Accounting Officer |
|
2015-07-23 |
4 |
AS |
$0.62 |
$120 |
D/D |
(194) |
147,121 |
|
- |
|
Bilinsky Igor |
Sr VP, Corporate Development |
|
2015-07-13 |
4 |
AS |
$0.70 |
$879 |
D/D |
(1,258) |
193,798 |
|
- |
|
Samant Vijay B |
President & CEO |
|
2015-07-13 |
4 |
AS |
$0.70 |
$3,310 |
D/D |
(4,737) |
1,146,301 |
|
- |
|
Smith Lawrence Russell |
VP, Vaccine Research |
|
2015-07-13 |
4 |
AS |
$0.70 |
$680 |
D/D |
(974) |
243,029 |
|
- |
|
Morrow George J |
Director |
|
2015-05-21 |
4 |
A |
$0.01 |
$75 |
D/D |
7,500 |
27,347 |
|
- |
|
Sherwin Stephen A |
Director |
|
2015-05-21 |
4 |
A |
$0.01 |
$75 |
D/D |
7,500 |
22,003 |
|
- |
|
Beleson Richard M |
Director |
|
2015-05-21 |
4 |
A |
$0.01 |
$75 |
D/D |
7,500 |
22,078 |
|
- |
|
Lyons Gary A |
Director |
|
2015-05-21 |
4 |
A |
$0.01 |
$75 |
D/D |
7,500 |
78,281 |
|
- |
|
Merton Robert C |
Director |
|
2015-05-21 |
4 |
A |
$0.01 |
$75 |
D/D |
7,500 |
90,781 |
|
- |
|
Douglas R Gordon |
Director |
|
2015-05-21 |
4 |
A |
$0.01 |
$75 |
D/D |
7,500 |
108,281 |
|
- |
|
Ramos Anthony Alan |
VP, Chief Accounting Officer |
|
2015-04-23 |
4 |
AS |
$1.01 |
$195 |
D/D |
(193) |
147,315 |
|
- |
|
Samant Vijay B |
President & CEO |
|
2015-04-13 |
4 |
AS |
$0.93 |
$4,411 |
D/D |
(4,738) |
1,151,038 |
|
- |
|
Smith Lawrence Russell |
VP, Vaccine Research |
|
2015-04-13 |
4 |
AS |
$0.93 |
$909 |
D/D |
(974) |
244,003 |
|
- |
|
Bilinsky Igor |
Sr VP, Corporate Development |
|
2015-04-13 |
4 |
AS |
$0.93 |
$1,173 |
D/D |
(1,257) |
195,056 |
|
- |
|
Samant Vijay B |
President & CEO |
|
2015-03-30 |
4 |
AS |
$0.91 |
$50,149 |
D/D |
(55,000) |
1,155,776 |
|
- |
|
Ramos Anthony Alan |
VP, Chief Accounting Officer |
|
2015-01-21 |
4 |
AS |
$1.09 |
$467 |
D/D |
(428) |
147,508 |
|
- |
|
Ramos Anthony Alan |
VP, Chief Accounting Officer |
|
2015-01-19 |
4 |
A |
$0.01 |
$600 |
D/D |
60,000 |
147,936 |
|
- |
|
Bilinsky Igor |
Sr VP, Corporate Development |
|
2015-01-19 |
4 |
A |
$0.01 |
$700 |
D/D |
70,000 |
196,313 |
|
- |
|
Samant Vijay B |
President & CEO |
|
2015-01-19 |
4 |
A |
$0.01 |
$3,000 |
D/D |
300,000 |
1,210,776 |
|
- |
|
Smith Lawrence Russell |
VP, Vaccine Research |
|
2015-01-19 |
4 |
A |
$0.01 |
$700 |
D/D |
70,000 |
244,977 |
|
- |
|
Samant Vijay B |
President & CEO |
|
2015-01-13 |
4 |
AS |
$1.12 |
$5,312 |
D/D |
(4,737) |
910,776 |
|
- |
|
Smith Lawrence Russell |
VP, Vaccine Research |
|
2015-01-12 |
4 |
AS |
$1.16 |
$2,210 |
D/D |
(1,912) |
174,977 |
|
- |
|
Bilinsky Igor |
Sr VP, Corporate Development |
|
2015-01-12 |
4 |
AS |
$1.16 |
$1,544 |
D/D |
(1,335) |
126,313 |
|
- |
|
583 Records found
|
|
Page 10 of 24 |
|
|